Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure
This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function tests).
• Male or female, aged 18-60 years
• Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition/EASL criteria)
• Etiology other than acetaminophen overdose (viral hepatitis HAV/HBV/HEV, non-acetaminophen drug-induced liver injury, or idiopathic)
• No NAC treatment received for current episode prior to enrollment